RxDoctor Payments Data

Danielle Duane, NP

Family · Athens, GANPI 1710239504

Payments from drug & device makers

$4,278in general payments, 2019–2025

Across 251 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$958
  • Abbott$354
  • Boston Scientific$314
  • Amgen$289
  • AstraZeneca$230
  • plus $969 from 13 others

What the payments were for

  • Food & beverage$4,264100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,278 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,480
Medicare patients
192
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan193$223,380
JardianceEmpagliflozin116$155,674
EliquisApixaban149$141,302
FarxigaDapagliflozin Propanediol116$140,641
XareltoRivaroxaban11$17,138
Torsemide154$2,842
Metoprolol Succinate288$2,665
Potassium Chloride122$1,891
Atorvastatin Calcium129$1,765
Spironolactone220$1,467
Carvedilol160$1,374
Amiodarone Hcl24$1,301
Furosemide169$899
Hydralazine Hcl46$812
Losartan Potassium81$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$958$223,380193 claims
Boehringer IngelheimJardiance$58$155,674116 claims
PfizerEliquis$102$141,302149 claims
AstraZenecaFarxiga$230$140,641116 claims
Johnson & JohnsonXarelto$124$17,13811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →